Journal article
Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant
Abstract
We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined thalidomide and prednisone maintenance in multiple myeloma. Eligibility required administration of melphalan (200 mg/m2) with blood stem cell support within 1 year of treatment onset and initiation of maintenance within 60 to 100 days after stem cell infusion. All patients received 50 mg of prednisone by mouth on alternate days and thalidomide at …
Authors
Stewart AK; Chen CI; Howson-Jan K; White D; Roy J; Kovacs MJ; Shustik C; Sadura A; Shepherd L; Ding K
Journal
Clinical Cancer Research, Vol. 10, No. 24, pp. 8170–8176
Publisher
American Association for Cancer Research (AACR)
Publication Date
December 15, 2004
DOI
10.1158/1078-0432.ccr-04-1106
ISSN
1078-0432